This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Extracorporeal Life Support in COVID‐19‐Related Acute Respiratory Distress Syndrome – A EuroELSO International Survey
In this article by the COVEC Study Group, they conducted a EuroELSO international survey investigating the clinical outcomes of extracorporeal membrane oxygenation (ECMO) on patients with COVID-19 Acute Respiratory Distress Syndrome (ARDS). They demonstrate that the majority of patients requiring ECMO were veno-venous rather than veno-arterial cannulation, with time on ECMO ranging between less than two weeks to more than four weeks. The majority stated that the reason for discontinuation of ECMO were lack of patient recovery at just over 50%, with the majority stating that they felt patients with COVID-19 and ARDS benefitted from ECMO therapy.